Drug intelligence / Profile preview

RES-701-1

Development stage: Discontinued
Lead developer: Kyowa Kirin
Modality: Peptides
Administration: Intravenous

Overview

**RES-701-1** is a unique cyclic polypeptide consisting of 16 common L-amino acids, produced by a Streptomyces species. It is a highly potent and selective **endothelin type B (ETB) receptor antagonist**, known for blocking the binding of endothelin-1 (ET-1) to ETB receptors but not to ETA receptors. RES-701-1 is highly stable against proteolysis and has been used as a molecular tool to probe the physiological functions of ETB receptors, which are involved in vascular regulation and neurologic pathways[1][3][4]. Its mechanism is relevant in cerebral infarct modeling and vascular research[5].

Targets

EDNRB (Endothelin receptor type B)

Beyond the preview

Go deeper on RES-701-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RES-701-1.

Explore the full profile